Durable natural killer cell responses after heterologous two-dose Ebola vaccination
Abstract Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo (EBOVAC2 consortium, EU Innovative M...
Guardado en:
Autores principales: | Helen R. Wagstaffe, Giada Susannini, Rodolphe Thiébaut, Laura Richert, Yves Lévy, Viki Bockstal, Jeroen N. Stoop, Kerstin Luhn, Macaya Douoguih, Eleanor M. Riley, Christine Lacabaratz, Martin R. Goodier |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9fcd68f95a2b493f8092a3429bbfd28d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
por: Houreratou Barry, et al.
Publicado: (2021) -
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Houreratou Barry, et al.
Publicado: (2021) -
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Ramon Roozendaal, et al.
Publicado: (2020) -
Long-lasting severe immune dysfunction in Ebola virus disease survivors
por: Aurélie Wiedemann, et al.
Publicado: (2020) -
Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol
por: Jean-Pierre Van Geertruyden, et al.
Publicado: (2021)